全文获取类型
收费全文 | 10765篇 |
免费 | 966篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 306篇 |
妇产科学 | 297篇 |
基础医学 | 1498篇 |
口腔科学 | 160篇 |
临床医学 | 1627篇 |
内科学 | 1933篇 |
皮肤病学 | 141篇 |
神经病学 | 1074篇 |
特种医学 | 263篇 |
外科学 | 1036篇 |
综合类 | 196篇 |
一般理论 | 26篇 |
预防医学 | 1430篇 |
眼科学 | 266篇 |
药学 | 814篇 |
中国医学 | 14篇 |
肿瘤学 | 635篇 |
出版年
2023年 | 116篇 |
2022年 | 127篇 |
2021年 | 274篇 |
2020年 | 210篇 |
2019年 | 315篇 |
2018年 | 350篇 |
2017年 | 256篇 |
2016年 | 277篇 |
2015年 | 308篇 |
2014年 | 406篇 |
2013年 | 565篇 |
2012年 | 783篇 |
2011年 | 804篇 |
2010年 | 437篇 |
2009年 | 372篇 |
2008年 | 627篇 |
2007年 | 675篇 |
2006年 | 622篇 |
2005年 | 640篇 |
2004年 | 589篇 |
2003年 | 546篇 |
2002年 | 423篇 |
2001年 | 148篇 |
2000年 | 120篇 |
1999年 | 127篇 |
1998年 | 120篇 |
1997年 | 80篇 |
1996年 | 71篇 |
1995年 | 64篇 |
1994年 | 71篇 |
1993年 | 68篇 |
1992年 | 87篇 |
1991年 | 68篇 |
1990年 | 62篇 |
1989年 | 61篇 |
1988年 | 65篇 |
1987年 | 40篇 |
1986年 | 50篇 |
1985年 | 51篇 |
1984年 | 55篇 |
1983年 | 28篇 |
1982年 | 37篇 |
1979年 | 35篇 |
1978年 | 36篇 |
1973年 | 34篇 |
1972年 | 31篇 |
1971年 | 27篇 |
1969年 | 28篇 |
1968年 | 34篇 |
1966年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
3.
4.
5.
6.
7.
Matthew J Matasar Ellen K Ritchie Nathan Consedine Carol Magai Alfred I Neugut 《European journal of cancer prevention》2006,15(4):367-370
Despite significant improvements in the prognosis of acute promyelocytic leukemia brought about by therapeutic advances, understanding of the epidemiology of acute promyelocytic leukemia remains limited. Earlier reports have suggested that Hispanics may have an increased incidence of acute promyelocytic leukemia, but no systematic analysis of national data has yet been reported. We performed a retrospective cohort study, using data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute from 1992-2001 in order to compare leukemia incidence rates as a function of race and ethnicity. We identified 709 cases of acute promyelocytic leukemia and analyzed incidence rates by race and sex. Hispanics were not found to have greater lifetime incidence rates than whites, with an incidence relative rate (IRR) of 0.86 that of whites (P=0.17). The age distribution among Hispanics was significantly different from non-Hispanic whites, with greater incidence rates for children ages 1-19 years (IRR=1.9, P=0.02) and adult ages 20-44 years (IRR=1.6, P=0.004). Blacks had lower lifetime incidence rates than non-Hispanic whites (IRR=0.75, P=0.04), Hispanics (IRR=0.64, P=0.007), and Asians (IRR=0.67, P=0.03). Asians did not differ from non-Hispanic whites in lifetime or age-specific incidence rates. These results indicate that while US Hispanics do not have greater lifetime incidence rates of acute promyelocytic leukemia, blacks have lower incidence rates of acute promyelocytic leukemia than Hispanics, non-Hispanic whites, and Asians. 相似文献
8.
9.
10.